CA
AMRX icon

Clearstead Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Clearstead Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70 Buy
+4
New +$55 ﹤0.01% 3420
2026
Q1 		– Sell
-1
Closed -$13 – 2272
2025
Q4 		$13 Sell
1
-199
-100% -$2.28K ﹤0.01% 2706
2025
Q3 		$2K Buy
200
+174
+669% +$1.56K ﹤0.01% 2448
2025
Q2 		$211 Buy
+26
New +$196 ﹤0.01% 2564

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Clearstead Advisors's AMRX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 4 shares worth $70. The stake represents ﹤0.01% of the portfolio and ranks #3420 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in AMRX as recently as Q4 2025.

Clearstead Advisors first reported a position in AMRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $2K in Q3 2025. 123 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Clearstead Advisors held 4 shares of Amneal Pharmaceuticals worth $70 as of Q2 2026.
  • Amneal Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3420 holding.
  • Clearstead Advisors first reported a position in Amneal Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Clearstead Advisors's Amneal Pharmaceuticals position peaked at $2K in Q3 2025.
  • 123 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.